← Back to homeFDA Clears Novartis Drug Cosentyx for Polymyalgia Rheumatica
Novartis wins a new U.S. use for its psoriasis and arthritis drug, giving adults with an inflammatory condition an option besides long-term steroids.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources Brief
The Food and Drug Administration cleared Novartis's Cosentyx for adults with polymyalgia rheumatica, the company announced on…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
5 confirmed facts and 2 sources behind this story.
By NewsPlain Editorial Team · Published
About this story
We haven’t published a correction to this story.
How NewsPlain works ← Back to home